# A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

> clinical trial · VERIFIED · 2026-07-09

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Primary Immune Thrombocytopenia (ITP)

- Company: Novartis Pharmaceuticals
- Sector: Primary Immune Thrombocytopenia (ITP)
- Primary source: https://clinicaltrials.gov/study/NCT07421167

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.